NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Helfand M, Muzyk T, Garzotto M. Benign Prostatic Hyperplasia (BPH) Management in Primary Care: Screening and Therapy [Internet]. Washington (DC): Department of Veterans Affairs (US); 2007 Feb.

Cover of Benign Prostatic Hyperplasia (BPH) Management in Primary Care

Benign Prostatic Hyperplasia (BPH) Management in Primary Care: Screening and Therapy [Internet].

Show details

REFERENCES

1.
Fitzpatrick JM, Kirby RS. Two-drug therapy is best for symptomatic prostate enlargement: could a combination of doxazosin and finasteride change clinical practice? BJU International. 2004;93(7):914–5. [PubMed: 15142134]
2.
McDonald H, et al. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia. Canadian Journal of Urology. 2004;11(4):2327–40. [PubMed: 15380054]
3.
McConnell JD, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. New England Journal of Medicine. 2003;349(25):2387–98. [PubMed: 14681504]
4.
Roehrborn CG. Drug treatment for LUTS and BPH: New is not always better. European Urology. 2006;49(1):5–7. [PubMed: 16314029]
5.
Therapeutics Letter. 2006. Benign Prostatic Hypertrophy: An update on drug therapy.
6.
Clifford GM, Farmer RD. Medical therapy for benign prostatic hyperplasia: a review of the literature. European Urology. 2000;38(1):2–19. [PubMed: 10859436]
7.
Edwards JE, MRA Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials. BMC Urol. 2002;2:1–17. [PMC free article: PMC140032] [PubMed: 12477383]
8.
Andersen J, et al. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology. 1997;49:839–845. [PubMed: 9187688]
9.
Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha1-adrenoceptor antagonists. BJU International. 2005;95(Suppl 4):29–36. [PubMed: 15871733]
10.
Wilt TJ, Howe W, MacDonald R. Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects. BJU International. 2002;89(3):214–25. [PubMed: 11856101]
11.
Wilt TJ, MacDonald R, Nelson D. Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. Cochrane Database of Systematic Reviews. 2002;(4) [PubMed: 11743300]
12.
MacDonald R, Wilt TJ, Howe RW. Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. BJU International. 2004;94(9):1263–70. [PubMed: 15610102]
13.
Djavan B, Marberger M. A Meta-Analysis on the Efficacy and Tolerability of alpha1-Adrenoceptor Antagonists in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction. Eur Urol. 1999;36:1–13. [PubMed: 10364649]
14.
Barendrecht MM, et al. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. BJU International. 2005;95(Suppl 4):19–28. [PubMed: 15871732]
15.
Kaplan SA, et al. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology. 2001;57:1073–7. [PubMed: 11377309]
16.
Auerbach SM, et al. Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology. 2004;64(5):998–1003. discussion 1003–4. [PubMed: 15533493]
17.
Fawzy A, et al. Long-term (4 year) efficacy and tolerability of doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension. International Journal of Urology. 1999;6(7):346–54. [PubMed: 10445304]
18.
Guthrie RM, Siegel RL. A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: the Hypertension and BPH Intervention Trial (HABIT) Clinical Therapeutics. 1999;21(10):1732–48. [PubMed: 10566569]
19.
Kirby RS. Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men. British Journal of Urology. 1998;82(3):373–9. [PubMed: 9772873]
20.
Lowe FC. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clinical Therapeutics. 1997;19(4):730–42. [PubMed: 9377617]
21.
Lowe FC, Olson PJ, Padley RJ. Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications. Urology. 1999;54(1):81–5. [PubMed: 10414731]
22.
Muzzonigro G. Tamsulosin in the treatment of LUTS/BPH: an Italian multicentre trial. Archivio Italiano di Urologia, Andrologia. 2005;77(1):13–7. [PubMed: 15906783]
23.
Sugaya K, et al. Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia. International Journal of Urology. 2003;10(11):569–74. discussion 575. [PubMed: 14633079]
24.
Suzuki H. Treatment of benign prostatic hyperplasia and hypertension in elderly hypertensive patients. British Journal of Urology. 1998;81(Suppl 1):51–5. [PubMed: 9589018]
25.
Lepor H, et al. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. Journal of Urology. 1998;160(4):1358–67. [PubMed: 9751354]
26.
Becopoulos T, Mitropoulos D, Christofis I. Influence of prostate size on terazosin efficacy. International Journal of Urology. 1997;4(4):358–61. [PubMed: 9256324]
27.
Boyle P, et al. Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology. 2001;58(5):717–22. [PubMed: 11711348]
28.
Boyle P, Gould AL, Roehrborn C. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology. 1996;48:398–405. [PubMed: 8804493]
29.
McConnell JD, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998;338:557–63. [PubMed: 9475762]
30.
Wasson JH, Reda DJ, Bruskewitz RC. A comparison of transurethal surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med. 1995;332:75–79. [PubMed: 7527493]
31.
Kaplan SA, et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostatic volume of 25 Ml or greater. Journal of Urology. 2006;175:217–21. [PubMed: 16406915]
32.
Lepor H, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. New England Journal of Medicine. 1996;335(8):533–9. [PubMed: 8684407]
33.
Kirby RS, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial.[see comment] Urology. 2003;61(1):119–26. [PubMed: 12559281]
34.
Roberts RO, et al. Limitations of using outcomes in the placebo arm of a clinical trial of benign prostatic hyperplasia to quantify those in the community. Mayo Clinic Proceedings. 2005;80(6):759–64. [PubMed: 15948299]
35.
Meigs JB, et al. Incidence rates and risk factors for acute urinary retention: the Health Professionals Followup Study. Journal of Urology. 1999;162:376–82. [PubMed: 10411042]
36.
Roehrborn C, et al. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. The PLESS study group. European Urology. 2000;37(5):528–36. [PubMed: 10765090]
37.
Roehrborn CG. Reporting of acute urinary retention in BPH treatment trials: importance of patient follow-up after discontinuation and case definitions. Urology. 2002;59(6):811–5. [PubMed: 12031358]
38.
Jacobsen SJ, Girman CJ, Lieber MM. Natural history of benign prostatic hyperplasia. Urology. 2001;58(6 Suppl 1):5–16. discussion 16. [PubMed: 11750242]
39.
Hong SJ, et al. Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia: an observational cohort study. European Urology. 2003;44(1):94–9. discussion 99–100. [PubMed: 12814681]
40.
Roehrborn CG, et al. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. European Urology. 2002;42:1–6. [PubMed: 12121721]
41.
Roehrborn CG, et al. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: A comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology. 2001;58:210–6. [PubMed: 11489703]
42.
Crawford ED, et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. Journal of Urology. 2006;175(4):1422–6. discussion 1426–7. [PubMed: 16516013]
43.
Roehrborn C, et al. Serum prostate-specific antigen concentrations are a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hypertrophy. Urology. 1999;53:473–80. [PubMed: 10096369]
44.
Marberger M, et al. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. European Urology. 2000;38:563–8. [PubMed: 11096237]
45.
Roehrborn C, et al. AUA Guideline on the management of benign prostatic hyperplasia. American Urological Association Education and Research, Inc., (2003). 2006. Updated 2006 < http://auanet​.org/guidelines/bph.cfm>. (10/28/04)
46.
Bandolier. Long-term BPH treatment. 2004.
47.
Andriole G, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol. 2004;172:1314. [PubMed: 15371831]
48.
Thompson I, et al. The influence of finasteride on the development of prostate cancer. New England Journal of Medicine. 2003;349:215–224. [PubMed: 12824459]
49.
Etzioni RD, et al. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol. 2005;174(3):877–81. [PubMed: 16093979]
50.
Walsh PC. Re: Long-term effects of finasteride on prostate specific antigen levels: results from the Prostate Cancer Prevention Trial.[comment] Journal of Urology. 2006;176(1):409–10. author reply 410. [PubMed: 16753454]
51.
Andriole G, et al. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. Journal of Urology. 2005;174(6):2098–104. [PubMed: 16280736]
52.
Roehrborn CG, et al. Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin. HYCAT Investigator Group. Hytrin Community Assessment Trial. Urology. 1997;50(4):556–61. [PubMed: 9338731]
53.
Andriole GL, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo controlled clinical trial. PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology. 1998;52:195. [PubMed: 9697781]
54.
Marks LS, et al. The Interpretation of Serum Prostate Specific Antigen in Men Receiving 5[alpha]-Reductase Inhibitors: A Review and Clinical Recommendations. The Journal of Urology. 2006;176(3):868–874. [PubMed: 16890642]
55.
Lee E, Lee C. Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. British Journal of Urology. 1997;80(4):606–11. [PubMed: 9352700]
56.
Na YJ, Guo YL, Gu FL. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. Journal of Medicine. 1998;29(5–6):289–304. [PubMed: 10503165]
57.
Narayan P, O’Leary MP, Davidai G. Early efficacy of tamsulosin versus terazosin in the treatment of men with benign prostatic hyperplasia: a randomized, open-label trial. J Appl Res. 2005;5:237–245.
58.
Okada H, et al. A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. BJU International. 2000;85(6):676–81. [PubMed: 10759664]
59.
Samli MM, Dincel C. Terazosin and doxazosin in the treatment of BPH: results of a randomized study with crossover in non-responders. Urologia Internationalis. 2004;73(2):125–9. [PubMed: 15331896]
60.
Tsujii T. Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. BPH Medical Therapy Study Group. Benign prostatic hyperplasia. International Journal of Urology. 2000;7(6):199–205. [PubMed: 10843450]
61.
Flannery MT, et al. Efficacy and safety of tamsulosin for benign prostatic hyperplasia: clinical experience in the primary care setting. Current Medical Research & Opinion. 2006;22(4):721–30. [PubMed: 16684433]
62.
Chung BH, Hong SJ, Lee MS. Doxazosin for benign prostatic hyperplasia: an open-label, baseline-controlled study in Korean general practice. International Journal of Urology. 2005;12(2):159–65. [PubMed: 15733110]
63.
Narayan P, Evans CP, Moon T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Journal of Urology. 2003;170(2 Pt 1):498–502. [PubMed: 12853808]
64.
Narayan P, Lepor H. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology. 2001;57(3):466–70. [PubMed: 11248621]
65.
Dutkiewicz S. Long-term treatment with doxazosin in men with benign prostatic hyperplasia: 10-year follow-up. International Urology & Nephrology. 2004;36(2):169–73. [PubMed: 15368687]
66.
Ichioka K, et al. Long-term treatment outcome of tamsulosin for benign prostatic hyperplasia. International Journal of Urology. 2004;11(10):870–5. [PubMed: 15479292]
67.
Palacio A, et al. Long-term study to assess the efficacy of tamsulosin in the control of symptoms and complications developed in patients with symptomatic benign prostatic hyperplasia (OMNICONTROL study): first-year follow-up report. Archivos Espanoles de Urologia. 2004;57(4):451–60. [PubMed: 15270291]
68.
Schulman CC, et al. Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group. European Urology. 1999;36(6):609–20. [PubMed: 10559616]
69.
Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology. 1998;51(6):901–6. [PubMed: 9609624]
70.
Roehrborn CG, et al. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology. 1996;47(2):159–68. [PubMed: 8607227]
71.
Michel MC, et al. Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? J Urol. 1998;160:784–91. [PubMed: 9720548]

Views

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...